[A20-58] Ribociclib (breast cancer, combination with fulvestrant) - Addendum to commission A20-22
Last updated 20.08.2020
Commission awarded on 06.07.2020 by the Federal Joint Committee (G-BA).
Initial endocrine therapy or after prior endocrine therapy in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer
Conclusion of dossier assessment A20-22 unchanged: for patients with initial endocrine therapy, indication of minor added benefit; for patients who have already received prior endocrine therapy, added benefit not proven.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A20-22||Ribociclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V||Commission completed|
Federal Joint Committee (G-BA)
2020-08-20: A G-BA decision was published.